Looks like you clickedhttps://www.urotoday.com/conference-highlights/esmo-2022/esmo-2022-prostate-cancer/139445-esmo-2022-cabazitaxel-every-2-weeks-versus-every-3-weeks-in-older-patients-with-mcrpc-the-cabasty-randomized-phase-iii-trial.html
If you do not want to visit that page, you can close this browser tab.
